Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01335581 · ClinicalTrials.gov registry record · NA
Study of Laser Treatment of Melasma
A NA study of Refractory Mixed Type Melasma, sponsored by ConBio, a Cynosure Company.
- Completed
- Registry status
- NA
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT01335581 is a NA study of Refractory Mixed Type Melasma that has completed, run by ConBio, a Cynosure Company. The registered enrollment target is 18 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01335581, a NA study of Refractory Mixed Type Melasma, has completed, sponsored by ConBio, a Cynosure Company.
- COMPLETED
- Registry status
- NA
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the RevLite laser in the treatment of refractory mixed type melasma.
Conditions Studied
Interventions
- DEVICE Q-Switched Nd:YAG Laser (RevLite)
- DRUG Retin-A and microdermabrasion
Study Locations (1)
New York
- New York Laser and Skin Care - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2011-04 |
| Est. Completion | 2012-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01335581
The ClinicalTrials.gov registry entry for NCT01335581 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ConBio, a Cynosure Company, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Refractory Mixed Type Melasma appearing as the primary indexed condition, and to 2 interventions - of which Q-Switched Nd:YAG Laser (RevLite) is the first listed.
NCT01335581 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT01335581 about?
NCT01335581 is a clinical study titled "Study of Laser Treatment of Melasma". The purpose of this study is to evaluate the RevLite laser in the treatment of refractory mixed type melasma.
What is the current status of trial NCT01335581?
This trial is currently completed. It is a NA study. The enrollment target is 18 participants. The study started on 2011-04. Estimated completion is 2012-03.
What conditions does trial NCT01335581 study?
This clinical trial studies the following conditions: Refractory Mixed Type Melasma.
What interventions are being tested in trial NCT01335581?
The interventions under investigation include: Q-Switched Nd:YAG Laser (RevLite) (DEVICE), Retin-A and microdermabrasion (DRUG).
Who is sponsoring clinical trial NCT01335581?
This trial is sponsored by ConBio, a Cynosure Company, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01335581 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.